memantine has been researched along with Parkinson Disease, Secondary in 5 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| " After memantine was started he developed severe fluctuations in awareness, visual hallucinations, agitation, and worsened parkinsonism." | 3.73 | Exacerbation of Lewy bodies dementia due to memantine. ( Blazquez-Menes, B; Calatayud, MT; Menendez-Gonzalez, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwamoto, K | 1 |
| Ikeda, K | 1 |
| Mizumura, S | 1 |
| Tachiki, K | 1 |
| Yanagihashi, M | 1 |
| Iwasaki, Y | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Menendez-Gonzalez, M | 1 |
| Calatayud, MT | 1 |
| Blazquez-Menes, B | 1 |
| Danysz, W | 1 |
| Parsons, CG | 1 |
| Kornhuber, J | 1 |
| Schmidt, WJ | 1 |
| Quack, G | 1 |
| Kucheryanu, VG | 1 |
| Kryzhanovskii, GN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for memantine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Topics: Amantadine; Animals; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Memantine; Parkinson D | 1997 |
4 other studies available for memantine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Combined treatment of methylprednisolone pulse and memantine hydrochloride prompts recovery from neurological dysfunction and cerebral hypoperfusion in carbon monoxide poisoning: a case report.
Topics: Antiparkinson Agents; Carbon Monoxide Poisoning; Cerebrovascular Circulation; Cerebrovascular Disord | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
Exacerbation of Lewy bodies dementia due to memantine.
Topics: Aged; Alzheimer Disease; Dopamine Agonists; Hallucinations; Humans; Lewy Body Disease; Male; Memanti | 2005 |
Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Excitatory Amino Acid Antagonists; Glutamic A | 2000 |